RxDoctor Payments Data

Lenda Barrett, APRN

Nurse Practitioner · West Columbia, SCNPI 1457965501

Payments from drug & device makers

$4,110in general payments, 2019–2025

Across 157 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$515
  • Bayer$502
  • AstraZeneca$487
  • Aurinia Pharma U.S., Inc.$394
  • Otsuka America Pharmaceutical, Inc.$300
  • Travere Therapeutics, Inc.$285
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$3,97897%
  • Education$1323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,110 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$48,392
Medicare patients
259
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol84$74,404
XphozahTenapanor Hcl13$66,488
VelphoroSucroferric Oxyhydroxide14$30,941
JanuviaSitagliptin Phosphate27$29,517
ProcritEpoetin Alfa38$27,418
AuryxiaFerric Citrate13$20,672
EliquisApixaban33$19,449
LokelmaSodium Zirconium Cyclosilicate19$14,400
JardianceEmpagliflozin15$10,286
RetacritEpoetin Alfa-Epbx22$9,291
Sevelamer Carbonate44$6,500
Midodrine Hcl52$2,699
Febuxostat15$1,105
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide14$991
Losartan Potassium131$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$487$88,804103 claims
Fresenius USA Marketing, Inc.Velphoro$271$30,94114 claims
Akebia Therapeutics IncAuryxia$224$20,67213 claims
Boehringer IngelheimJardiance$69$10,28615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →